15.25
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aerie Pharmaceuticals Inc | AERI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 15.25 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 15.25 | 15.25 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.81 - 15.37 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 15.25 | USD |
Period:
Draw Mode:
Aerie Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 753.62M | 49.42M | 48.57M | $ 194.13M | $ -39.35M | -1.62 | -20.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -1.04k | 3.10% |
Aerie Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AERI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 15.21 | 15.25 | 15.21 | 15.24 | 521,168 | 0.04 | 0.26% |
| 3 Months | 15.17 | 15.26 | 15.04 | 15.18 | 786,519 | 0.08 | 0.53% |
| 6 Months | 4.92 | 15.37 | 4.81 | 13.39 | 1,115,421 | 10.33 | 209.96% |
| 1 Year | 9.95 | 15.37 | 4.81 | 10.76 | 1,036,109 | 5.30 | 53.27% |
| 3 Years | 19.27 | 26.26 | 4.81 | 13.45 | 832,936 | -4.02 | -20.86% |
| 5 Years | 65.70 | 74.75 | 4.81 | 21.75 | 754,338 | -50.45 | -76.79% |
Aerie Pharmaceuticals Description
| Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America. |